English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), a group of novel antidiabetic agents, demonstrated beneficial cardiovascular effects in recent large, placebo-controlled randomised clinical trials (RCTs); their clear antiarrhythmic benefit has not been yet underlined. The purpose of the present meta-analysis is to clarify the impact of GLP-1RAs on different types of cardiac arrhythmias. We searched PubMed from its inception up to 8 October 2020 for all available cardiovascular and renal outcome, placebo-controlled RCTs utilising GLP-1RAs versus placebo. The present meta-analysis is reported according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) statement. We included data from 7 RCTs with GLP-1RAs in a total of 55,943 participants. Treatment with GLP-1RAs did not provide significant benefit in the risk for atrial fibrillation (RR = 0.81, 95%CI; 0.78–1.15,  I2  = 51%), atrial flutter (RR = 0.79, 95%CI; 0.53–1.16,  I2  = 0%), ventricular fibrillation (RR = 0.99, 95%CI; 0.48–2.04,  I2  = 0%), ventricular tachycardia (RR = 1.41, 95%CI; 0.87–2.28,  I2  = 10%), atrial tachycardia (RR = 0.63, 95%CI; 0.10–3.90,  I2  = 24%), sinus node dysfunction (RR = 0.70, 95%CI; 0.40–1.23,  I2  = 0%), ventricular extrasystoles (RR = 1.37, 95%CI; 0.56–3.30,  I2  = 0%), second-degree atrioventricular block (RR = 0.96, 95%CI; 0.52–1.74,  I2  = 0%) or complete atrioventricular block (RR = 0.78, 95%CI; 0.39–1.54,  I2  = 38%). In patients with type 2 diabetes mellitus, treatment with GLP-1RAs does not significantly affect the risk for major cardiac arrhythmias.

Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias